



**Supplementary Information for:**

**Lewandowski et al., The *Firre* locus produces a trans-acting RNA molecule that functions in hematopoiesis**




**c**

```



cggagctctagggctcctttatgtagcaaagtcaggcctgggaacagaactcatg
tgctgtaaaaagtcctcaggtgcgctcctcggtggtttagagactggagaggaatg
ggggcggggggaacaaaatccgaggacagtcgagccaagaaaagtcggggcttcta
ggatgccaaccacgccaacagatcaaaaccaggactggaggactgaagatgaagc
cggcaaaaagtcaccagccacggctcttgaaggtatgcttcacctctctgctaa
gtcttcatccctgtctatgaggacaaagaagtacgggttaaattggcgatgggcc
aggcgctccttgaggatgctctaaagttggtgatagaaaatgggagaactgaagac
aaccactttataaaacccttgctgcttgaattgt

```



**Supplementary Figure 1: Schematization of the targeted *Firre* locus and genotyping. (A)** Targeted *Firre* locus shown in reverse orientation. Targeting cassettes containing hygromycin and neomycin cassettes shown as light gray rectangles and the loxP sites shown as dark gray triangles. Cre-mediated recombined allele shown below as a red line with a single loxP site. Arrows indicate genotyping primers used to amplify alleles for: *Firre* WT, black; knockout allele (KO), red; hygromycin (hyg), light gray; and neomycin (neo), blue. **(B)** Genotyping gel for: *Firre*<sup>flxed</sup> (*fl/fl*); *Firre* heterozygous (*+/-*); and *Firre* knockout (*-/-*) mice. Alleles amplified indicated below the gel. **(C)** DNA sequence used to generate a *Firre* riboprobe.




**Supplementary Figure 2. Weight measurements and skeletal analysis of  $\Delta$ Firme mice. (A)** Body weight measurements in grams (g) for male WT (n=38) (gray) and  $\Delta$ Firme (n=35) (red), and **(B)** female WT (n=21) (gray) and  $\Delta$ Firme (n=29) (red) mice over 12 weeks. Data shown as a box and whisker plot with error bars showing the minimum and maximum, the significance was determined using a two-tailed t-test. **(C-G)** Skeletal preparations of E18.5 WT (n=8) and  $\Delta$ Firme (n=7) mice stained with alcian blue (cartilage) and alizarin red (bone) show that  $\Delta$ Firme mice appear to have normal skeletal development. **(D)** Rib cages from E18.5 wild-type (n=8)  $\Delta$ Firme (n=7) showing that  $\Delta$ Firme embryos have a normal number of ribs. **(E)** Skulls from E18.5 WT (n=8) and  $\Delta$ Firme (n=7) embryos show normal morphology. Abbreviations used: n, nasal; f, frontal bone; p, parietal; ip, interparietal; s, supraoccipital; e, exoccipital; md, mandible; and x, maxillary. **(F)** Limb patterning and ossification appears normal in WT (n=8) and  $\Delta$ Firme mice (n=7). Abbreviations used: sc, scapula; cl, clavicle; hu, humerus; ra, radius; and ul, ulna. **(G)** Vertebrae patterning and ossification appears normal in WT (n=8) and  $\Delta$ Firme (n=7) embryos. **(H)** The total number of vertebrae in E18.5 WT (n=4) and  $\Delta$ Firme (n=5) embryos do not significantly differ (P=0.876, two-tailed unpaired t-test). Data plotted showing the mean  $\pm$  SEM. **(I)** The number of vertebrae per: c, cervical; t, thoracic; l, lumbar, and s, sacral segments in E18.5  $\Delta$ Firme (n=5) embryos is the same as found in WT (n=4).




**Supplementary Figure 3. Deletion of *Firre* does not impact X chromosome inactivation or change expression of *Xist* RNA.** (A) *Xist* RNA expression (FPKM) in eight female tissues from RNA-seq in WT (n=3) and  $\Delta$ *Firre* (n=3) at E11.5. Data are shown as mean  $\pm$  SEM. (B,C) Co-DNA/RNA FISH in female *Firre*<sup>+/-</sup> MEFs. DNA FISH for the WT *Firre* locus shown in red and *Xist* RNA shown in green. Scale bar equals 10 micrometers. Quantification of localization of *Xist* RNA with the WT *Firre* locus for three independent *Firre*<sup>+/-</sup> MEFs. Cis indicates a co-localization between the WT *Firre* DNA locus and *Xist* RNA and trans indicates *Xist* RNA did not co-localize with the WT *Firre* DNA locus.




**Supplementary Figure 4. Mice overexpressing Firre do not have increased serum cytokines. (A)** Experimental schematic for cytokine measurements in 5-7 weeks old mice injected with either saline or LPS. **(B)** Cytokine measurements in serum at 5 hours post saline or LPS injection from control saline injected mice (WT or tg(*Firre*) fed a dox diet, n=3, black diamonds), *Firre*<sup>OE</sup> saline injected mice fed a dox diet (n=3, blue triangles), and WT mice fed a normal diet injected with 5 mg/kg LPS (specific-activity) (n=3 to 4, gray circles). Data are shown as mean  $\pm$  SEM and statistical significance determined using a two-tailed unpaired t-test.



**Supplementary Figure 5. Immunophenotyping in WT,  $\Delta$ Firre, and  $Firre^{OE}$  mice. (A)** Frequency of B cells in the peripheral blood shown as percent (%) of live cells from WT (n=17) and  $\Delta$ Firre mice (n=18). Three representative experiments combined (seven independent experiments). **(B)** Frequencies of double negative (DN) (DN1, DN2, DN3, DN4), double positive (DP), single positive (SP) CD4, and SP CD8 cells in thymuses shown as percent of live cells from WT (n=8) and  $\Delta$ Firre (n=8) mice. Enumeration of cells shown below as cells per  $\mu$ L of thymus. A representative experiment shown (three independent experiments). **(C)** Frequencies of HSC and MPP cell populations from total bone marrow (BM) shown as percent of live cells from WT (n=13) and  $\Delta$ Firre (n=12) mice. Enumeration of cells shown below as cells per  $\mu$ L of bone marrow. Two representative experiments combined (three independent experiments). **(D)** Frequency of B cells in the peripheral blood shown as percent of live cells from control (tg(Firre), WT, or rtTA with dox) (n=6) and  $Firre^{OE}$  +dox (n=5) mice. One representative experiment shown (three independent experiments). **(E)** Frequencies of HSC and MPP cells from total BM shown as percent of live cells from control (tg(Firre), WT, or rtTA with dox) (n=10) and  $Firre^{OE}$  +dox mice (n=6) (two independent experiments). All data shown as mean  $\pm$  SEM and statistical significance determined using a two-tailed Mann Whitney-U test.




**Supplementary Figure 6.  $\Delta$ *Firre* HSCs are less competitive at repopulating blood in vivo. (A)** Schematic of competitive chimera HSC transplant experiment. HSC enriched population from age- and sex-matched *Firre* WT/CD45.2 (blue) or  $\Delta$ *Firre*/CD45.2 (red) combined with PepBoy/CD45.1 (gray) at a 1:1 ratio and transplanted into lethally irradiated PepBoy/CD45.1 recipient male mice. **(B)** Representative flow cytometry plots from WT showing the FACS strategy used for isolating an HSC-enriched population for transplant from lineage depleted total bone marrow. **(C)** Frequencies of donor-derived CD45.2 CD4, CD8, NK, and B cells at 23 weeks post competitive chimera transplant for *Firre* WT/CD45.2 with PepBoy/CD45.1 (n=10), and  $\Delta$ *Firre*/CD45.2 with PepBoy/CD45.1 (n=10) (two independent experiments shown). Data are shown as mean  $\pm$  SEM and significance determined by a two-tailed Mann-Whitney U test.




**Supplementary Figure 7. Frequencies of NK cells in the blood in *Firre* transgenic mice. (A)** Representative flow cytometry plots of NK cells in WT and *Firre*<sup>rescue</sup> +dox mice. **(B)** Frequencies of NK cells shown as percent (%) of live cells in the peripheral blood from female mice 24 to 33 weeks old: dox-treated WT (n=5), dox-treated  $\Delta$ *Firre* (n=5), no dox *Firre*<sup>rescue</sup> (n=4), and dox-treated *Firre*<sup>rescue</sup> (n=5). Data are shown as mean  $\pm$  SEM, two independent experiments, and significance determined by using a two-tailed unpaired t-test.






**Supplementary Figure 8. Frequencies of CLPs in lineage-depleted bone marrow in *Firre* transgenic mice.** **(A)** Representative gating strategy for identifying CLPs in lineage depleted bone marrow (BM) from WT,  $\Delta$ *Firre*, and *Firre*<sup>rescue</sup> + dox mice. **(B)** Frequencies of CLPs shown as percent (%) of live cells in lineage depleted bone marrow over three experiments from male (7 to 10 weeks old, solid object) and female (19 to 24 weeks old, outlined object) mice: WT (n=9);  $\Delta$ *Firre* (n=9), and dox-treated *Firre*<sup>rescue</sup> (n=11). Data are plotted as the mean  $\pm$  SEM and significance determined by a two-tailed Mann-Whitney U test.



**Supplementary Figure 9. *Firre* does not regulate the expression of neighboring genes. (A-F)** *Firre* locus region (2 Mb) showing log<sub>2</sub> fold change (log<sub>2</sub> FC) gene expression differences (RNA-seq) between  $\Delta$ *Firre* and WT E11.5 tissues (forebrain, pre-somitic mesoderm (PSM), lung, hindlimb, liver, and midbrain). *Firre* is shown in red, significantly dysregulated genes are shown in red, genes with less than 1 FPKM expression are shown in gray, and genes that are not significantly changed are shown in black.



**Supplementary Figure 10. Representative gating strategies for flow cytometry. (A)** Gating strategy for thymocyte cell analysis: SP CD4 and CD8, DN 1-4, and DP CD4 and CD8. **(B)** Gating strategy in total bone marrow for CMP, CLP, HSC, and MPP cells. **(C)** Gating strategy in peripheral blood for B cell, NK, CD4, and CD8 cells.

Mating Genotype	Diet	Litters	Total pups	Mean litter size ( $\pm$ sd)	Progeny Genotype	Total number pups per genotype	♂	♀	n.d	P value
♂ <i>Firre</i> <sup>+ly</sup> x ♀ <i>Firre</i> <sup>+/+</sup>	Normal	6	39	6.5 $\pm$ 1.3	Wildtype	39	20	19	0	0.873
♂ <i>Firre</i> <sup>ly</sup> x ♀ <i>Firre</i> <sup>-/-</sup>	Normal	10	68	6.8 $\pm$ 1.9	$\Delta$ <i>Firre</i>	68	30	38	0	0.332
-----										
♂ rtTA x ♀ <i>Firre</i> <sup>OE</sup>	Control	10	66	6.6 $\pm$ 1.5	<i>Firre</i> <sup>OE</sup> ; rtTA	21	08	13	0	0.2752
					<i>Firre</i> <sup>OE</sup>	23	11	07	05	
					rtTA	11	03	01	07	
					Wildtype	09	02	04	03	
n.d	02									
♂ rtTA x ♀ <i>Firre</i> <sup>OE</sup>	Dox.	33	206	5.7 $\pm$ 1.7	<i>Firre</i> <sup>OE</sup> ; rtTA	41	19	22	0	0.6394
					<i>Firre</i> <sup>OE</sup>	76	35	28	13	
					rtTA	22	11	10	01	
					Wildtype	57	17	11	29	
					n.d	10				

**Supplementary Table 1. Loss or gain of *Firre* expression does not alter sex distribution. (A)** Deletion of the *Firre* locus does not significantly alter the distribution of male and female progeny from matings between male and female  $\Delta$ *Firre* mice, or in matings between male and female *Firre* WT mice (above dashed line). Matings between male rtTA and female *Firre*<sup>OE</sup> mice on a dox or control diet do not show a significant difference in the distribution of male and female progeny that overexpress or do not overexpress *Firre* (*Firre*<sup>OE</sup>; rtTA) (below dashed line). Tissue collection for genotyping performed at P7. Litter size shown as mean with standard deviation (s.d.), not determined (n.d.), Chi-square statistic reported (p-value).